Patients are telling the truth — just not to you
September 21, 2026 | Data, Social Listening, clinical trials, patients
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
There’s a familiar complaint in clinical research: patients don’t open up. They say they’re fine when they’re not. They under-report side effects. They nod through the consent conversation, and months later it’s clear they didn’t really follow it.
Spend an hour where patients talk to each other, though, and a different picture appears. They’re not guarded at all. They’re astonishingly honest — about what they fear, the side effects they hide, the days they can barely function. The truth isn’t missing. It’s just pointed somewhere other than the clinic.
That gap between what patients share with one another and what they tell the people providing their care is worth paying attention to. Because the things they don’t say out loud are usually the things a trial team most needs to hear.
What we miss in the room
It’s in patient communities where the quiet parts get said out loud.
On what it takes just to turn up, one person, deep into fertility treatment, wrote that they’d been going so long they had a favourite parking spot and no longer knew how to answer “how are you?” — “I am fine. I am functional.” The “fine” is doing a lot of work there.
On side effects, the honesty is sharper — and more uncomfortable. One cancer patient described hiding their symptoms “so I don’t have to wait another month for the next dose”.
Someone managing chronic pain put it plainly: they don’t tell the doctor about something that helps, “otherwise I’m an addict and not someone who needs help”. That isn’t non-compliance. It’s a calculation — that telling the truth might cost them their treatment.
Patients can also recognise when something isn’t right, sometimes before the clinical picture becomes clear. “The night of the procedure, I knew something was wrong,” one wrote — a concern later confirmed by the tests.
Some of this never gets said in the room. Some of it is said but not fully heard. All of it has value.
The silence isn’t soft — it shows up in your data
It’s tempting to file this under bedside manner. It isn’t. When patients don’t feel safe being honest, the consequences land exactly where a trial can least afford them.
Under-reported side effects create blind spots in safety data. The signals are there, they just aren’t always reaching you. Distress only becomes visible when someone quietly drops out. The burden of participation appears later as missed visits and withdrawals that seem to come from nowhere. A patient saying “I’m fine” isn’t a small social grace; it’s a missing data point. Honesty, in other words, isn’t a courtesy patients owe you. It’s the integrity of what you’re collecting.
Honesty is a design choice, not a personality trait
Patients aren’t withholding because they’re difficult or private. They’re withholding because, somewhere along the way, they learned that honesty has a cost — you lose the drug, you get dismissed, you become “the difficult one”, you worry people who already look worried.
So, the fix isn’t asking harder. It’s making honesty feel safer. That’s a design problem, and it runs through everything a participant touches: how a question is asked, how a reported side effect is met, whether the consent conversation invited questions or just collected a signature, whether the materials treat someone as an expert in their own condition or a beginner. Get those right and people tell you more, not because they suddenly trust strangers, but because the room made candour feel safer.
Start by listening where they’re already honest
If you want to understand what your participants aren’t saying, start where they’re already talking.
The version of the trial experience that rarely reaches the clinic already exists — in the open, in the communities where patients talk to one another. It will tell you which side effects people hide and why, what attending really costs, where the consent process loses them, and what they wish someone had asked. It’s the brief for every conversation you then design.
You don’t need to give people permission to speak openly in the abstract. Start by listening to what they’re already comfortable saying elsewhere. Then build the conditions where they’ll feel just as comfortable saying it to you.
Ready to talk?
Understanding what patients aren’t saying — and designing the materials and moments that help them say it — is what we do. If you want the real version of your participants’ experience, not just the version they feel able to share in clinic, let’s talk.
The patient voice here is drawn from public patient communities in our listening index, de-identified and lightly trimmed; medication names removed. It’s a self-selected, anonymous source — illustrative, not statistically representative — but it shows, in patients’ own words, the honest version they rarely say in clinic.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
When what matters to patients is hard to measure
Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.